ASE · Biotechnology

Kairos Pharma, Ltd. (KAPA) Stock

$0.96 +10.29% ASE: KAPA Healthcare

Valuation

MetricValue
Price$0.96
Market Cap$2.93M
P/E Ratio-0.81
P/B Ratio1.14
P/S Ratio0.00
EPS (TTM)$-0.30
52-Week High$9.59
52-Week Low$0.87
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-98.77%
ROA-130.27%
ROCE-143.93%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio10.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-1.0M$-2.0M$-2.0M$-6.0M
Net Profit$-2.0M$-1.0M$-2.0M$-3.0M$-5.0M
EPS$-1.19$-0.70$-1.19$-1.61$-2.10
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$1.0M$1.0M$6.0M$7.0M
Total Liabilities$2.0M$2.0M$3.0M$1.0M$0
Cash$0$0$0$1.0M$4.0M
Borrowings$0$1.0M$1.0M$0$0

Latest News

Kairos Pharma Collaborates With Bayer to Assess Prostate Cancer Treatment Combination MT Newswires · Jul 22, 2026 Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer Business Wire · Jul 22, 2026 CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever TMX Newsfile · Jul 15, 2026 Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market Business Wire · Jul 15, 2026 All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy Zacks · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$0$0$-4.0M$-3.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$4.0M
Net Cash Flow$0$0$0$1.0M$3.0M
Free Cash Flow$0$0$0$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA-0.38
FCF Yield-83.20%
Quick Ratio11.98
Interest Coverage0.00
Return 1Y-72.82%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLRAllarity Therapeutics, Inc. $1.00 +1.84% -1.33 $15.91M 0.00%
BCTXBriaCell Therapeutics Corp. $3.95 +0.77% -0.33 $34.36M 0.00%
CASICASI Pharmaceuticals, Inc. $0.15 +3.08% -0.07 $2.33M 0.00%
CINGCingulate Inc. $4.86 -0.51% -0.95 $65.39M 0.00%
CLSDClearside Biomedical, Inc. $0.41 +0.00% -0.11 $2.15M 0.00%

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd. is led by CEO John S. Yu, employs 1 people, headquartered in US, publicly traded since 2024.

Kairos Pharma, Ltd. (KAPA) stock trades at $0.96 with a market capitalization of $2.93M. The stock is valued at a price-to-earnings (P/E) ratio of -0.81, price-to-book of 1.14, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.87 and $9.59, and currently trades 90.0% below its 52-week high.

On profitability, Kairos Pharma, Ltd. generates a return on equity (ROE) of -98.77%, return on capital employed of -143.93%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.19 -0.04% JNJ Johnson & Johnson $259.19 +1.06% ABBV AbbVie Inc. $275.55 +1.15% MRK Merck & Company, Inc. Common Stock (new) $145.07 +1.89% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.47 +2.03% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $659.46 +1.15% AMGN Amgen Inc. $411.80 +1.07% GILD Gilead Sciences, Inc. $149.65 +1.73% ABT Abbott Laboratories $100.23 +1.76% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides